India, June 26 -- Viridian Therapeutics, Inc. (VRDN) announced that the U.S. FDA has approved Lumvoa for the treatment of thyroid eye disease, marking the company's first commercial product and a major milestone in its transition to a commercial-stage biopharma.
Thyroid eye disease (TED) is a rare autoimmune condition that causes inflammation and tissue changes behind the eyes, leading to bulging, double vision, pain, and in severe cases, vision loss. Until now, treatment options have been limited, leaving many patients with persistent symptoms.
Lumvoa (veligrotug-vvze) is a full antagonist of IGF-1R and the first approved treatment for TED with labeling that includes data for both active and chronic disease.
The approval was supported b...